May 15, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Tecentriq lands FDA approval as adjuvant treatment for muscle invasive bladder cancer
The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with muscle invasive bladder cancer. Atezolizumab (Tecentriq, Genentech) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) received approval as adjuvant treatments after cystectomy for adults with circulating tumor DNA molecular residual disease, as
560 words~3 min read
